HIV Drug Development Guidance From FDA Stresses Clinical Resistance Testing
Executive Summary
A finalized FDA guidance for antiretroviral drug development emphasizes HIV resistance testing and clinical analysis, rather than preclinical in vitro studies as outlined in the draft guidance. Templates for submitting resistance data on Hepatitis B and C virus also were dropped in the final version
You may also be interested in...
Merck Isentress Gets Advisory Panel Support But May Get Narrow Indication
Although divided on whether the indication for Merck's Isentress (raltegravir) should be narrowed, FDA's Antiviral Drugs Advisory Committee voted unanimously in favor of accelerated approval for the HIV drug on Sept. 5
Antiviral Resistance Analysis Requested In FDA Draft Guidance
An analysis of resistance activity associated with antiviral drugs should be conducted prior to the initiation of clinical studies, FDA recommends in a draft guidance released May 25
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.